Hospira's Nivestim approved in EU
This article was originally published in Scrip
Executive Summary
Hospira's Nivestim (filgrastim; 12MU (120µg), 30MU (300µg), 48MU (480µg)) solution for injection or infusion has been approved in the EU for the prevention of febrile neutropenia and reduction in duration of chemotherapy-induced neutropenia. Nivestim is a biosimilar of Amgen's Neupogen, which was the reference product for the application.